Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Influenza

Free Subscription 27.06.2022 3 Am J Med 12 Ann Intern Med 2 Antimicrob Agents Chemother 1 Antiviral Res 3 Biochem Biophys Res Commun 1 BMC Pediatr 8 BMJ 4 Epidemiol Infect 2 Eur J Epidemiol 3 J Clin Microbiol 2 J Exp Med 9 J Infect Dis 1 J Virol 12 JAMA 2 Lancet 3 MMWR Morb Mortal Wkly Rep 9 N Engl J Med 2 PLoS Comput Biol 2 PLoS Med 54 PLoS One 5 Proc Natl Acad Sci U S A 21 Vaccine

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Med

1. CACERES J, Maki DG, Hennekens CH
   Cautious Optimism and Considerations for Health Providers and Patients: Oral Antiviral for Early Treatment of High-Risk Patients and Vaccines for Prevention of COVID-19.
   Am J Med. 2022;135:808-809.
   PubMed        
   
   
2. LI W, Rios S, Nagraj S, Hajra A, et al
   Statin Use in Hospitalized Patients with COVID-19: A Comprehensive Analysis of the New York City Public Hospital System.
   Am J Med. 2022;135:897-905.
   PubMed         Abstract available
   
   
3. COHEN A
   Concerns About Our Public Medical Response to COVID 19.
   Am J Med. 2022;135:801-802.
   PubMed        
   
   

   
   Ann Intern Med

4. SMITH CA, Barnes GD
   Web Exclusive. Annals for Hospitalists Inpatient Notes - Venous Thromboembolism Prophylaxis in COVID-19: Making Sense of the Evidence.
   Ann Intern Med. 2022;175:HO2-HO3.
   PubMed        
   
   
5. KING D
   Patients surviving COVID-19 had increased risk for adverse mental health outcomes vs. persons without COVID-19.
   Ann Intern Med. 2022 Jun 7. doi: 10.7326/J22-0031.
   PubMed         Abstract available
   
   
6. SHAH A, O'Horo JC
   In patients with COVID-19 receiving IMV or ECMO, adding baricitinib to usual care reduced all-cause mortality.
   Ann Intern Med. 2022 Jun 7. doi: 10.7326/J22-0033.
   PubMed         Abstract available
   
   
7. VASSILOPOULOS A, Mylonakis E
   In patients with COVID-19 at risk for severe disease, nirmatrelvir + ritonavir reduced hospitalization or death.
   Ann Intern Med. 2022 Jun 7. doi: 10.7326/J22-0038.
   PubMed         Abstract available
   
   
8. ASSOUMOU SA, Peterson A, Ginman E, James T, et al
   Addressing Inequities in SARS-CoV-2 Vaccine Uptake: The Boston Medical Center Health System Experience.
   Ann Intern Med. 2022 May 17. doi: 10.7326/M22-0028.
   PubMed         Abstract available
   
   
9. MULL MCCRARY M
   Web Exclusive. Annals Story Slam - A Two-Year Long Blackjack Game: Decisions During COVID.
   Ann Intern Med. 2022;175:SS1.
   PubMed        
   
   
10. OHN-SAITH MAS
    Annals Story Slam - Three-Finger Salute to the COVID-19 Pandemic.
    Ann Intern Med. 2022 Apr 29:SS1. doi: 10.7326/W22-0010.
    PubMed        
    
    
11. CLARKE SR
    Web Exclusive. Annals Story Slam - The Prayer in the COVID Unit.
    Ann Intern Med. 2022;175:SS1.
    PubMed        
    
    
12. KOTTON CN
    Belt and Suspenders: Vaccines and Tixagevimab/Cilgavimab for Prevention of COVID-19 in Immunocompromised Patients.
    Ann Intern Med. 2022 Apr 12. doi: 10.7326/M22-1026.
    PubMed        
    
    
13. NUSSBAUM EZ, Thiriveedhi V, Uddin R, Cho HE, et al
    Implementation of a SARS-CoV-2 Genotyping Panel for Prompt Omicron Variant Identification: A Pragmatic Tool for Clinical Laboratories.
    Ann Intern Med. 2022 Mar 29. doi: 10.7326/M22-0023.
    PubMed        
    
    
14. BOUZID D, Visseaux B, Kassasseya C, Daoud A, et al
    Comparison of Patients Infected With Delta Versus Omicron COVID-19 Variants Presenting to Paris Emergency Departments : A Retrospective Cohort Study.
    Ann Intern Med. 2022 Mar 15. doi: 10.7326/M22-0308.
    PubMed         Abstract available
    
    
15. 
    Summary for Patients: Comparison of Patients Infected With Delta Versus Omicron COVID-19 Variants Presenting to Paris Emergency Departments.
    Ann Intern Med. 2022 Mar 15. doi: 10.7326/P22-0005.
    PubMed        
    
    

    
    Antimicrob Agents Chemother

16. LEEGWATER E, Moes DJAR, Bosma LBE, Ottens TH, et al
    Population Pharmacokinetics of Remdesivir and GS-441524 in Hospitalized COVID-19 Patients.
    Antimicrob Agents Chemother. 2022;66:e0025422.
    PubMed         Abstract available
    
    
17. PITTS J, Li J, Perry JK, Du Pont V, et al
    Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants.
    Antimicrob Agents Chemother. 2022;66:e0022222.
    PubMed         Abstract available
    
    

    
    Antiviral Res

18. JONES JC, Rovito SW, Penaflor MK, Webby RJ, et al
    Influenza A virus polymerase acidic protein E23R substitution is a marker of reduced susceptibility to baloxavir.
    Antiviral Res. 2022 Jun 20:105369. doi: 10.1016/j.antiviral.2022.105369.
    PubMed         Abstract available
    
    

    
    Biochem Biophys Res Commun

19. WEI W, Kong N, Liu MZ, Han T, et al
    Anisodamine potently inhibits SARS-CoV-2 infection in vitro and targets its main protease.
    Biochem Biophys Res Commun. 2022;616:8-13.
    PubMed         Abstract available
    
    
20. ZHANG B, Li Y, Feng Q, Song L, et al
    Structural insights into ORF10 recognition by ZYG11B.
    Biochem Biophys Res Commun. 2022;616:14-18.
    PubMed         Abstract available
    
    
21. SUGAMOTO K, Tanaka YL, Saito A, Goto Y, et al
    Highly polymerized proanthocyanidins (PAC) components from blueberry leaf and stem significantly inhibit SARS-CoV-2 infection via inhibition of ACE2 and viral 3CLpro enzymes.
    Biochem Biophys Res Commun. 2022;615:56-62.
    PubMed         Abstract available
    
    

    
    BMC Pediatr

22. SAWIRES R, Kuldorff M, Fahey M, Clothier H, et al
    Snotwatch: an ecological analysis of the relationship between febrile seizures and respiratory virus activity.
    BMC Pediatr. 2022;22:359.
    PubMed         Abstract available
    
    

    
    BMJ

23. SCOBIE S
    Covid-19: How has the pandemic differed across the four UK nations?
    BMJ. 2022;377:o1482.
    PubMed        
    
    
24. LI X, Ostropolets A, Makadia R, Shoaibi A, et al
    Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study.
    BMJ. 2021;373:n1435.
    PubMed         Abstract available
    
    
25. WISE J
    Covid-19: Omicron sub variants driving new wave of infections in UK.
    BMJ. 2022;377:o1506.
    PubMed        
    
    
26. TANNE JH
    Covid-19: CDC and FDA approve Pfizer and Moderna vaccines for under 5s.
    BMJ. 2022;377:o1507.
    PubMed        
    
    
27. WISE J
    Covid-19: Long covid risk is lower with omicron than delta, researchers find.
    BMJ. 2022;377:o1500.
    PubMed        
    
    
28. PAGEL C
    The covid waves continue to come.
    BMJ. 2022;377:o1504.
    PubMed        
    
    
29. WISE J
    Covid-19: Omicron infection is poor booster to immunity, study finds.
    BMJ. 2022;377:o1474.
    PubMed        
    
    
30. ADAB P, Haroon S, O'Hara ME, Jordan RE, et al
    Comorbidities and covid-19.
    BMJ. 2022;377:o1431.
    PubMed        
    
    

    
    Epidemiol Infect

31. DEN BOOGERT EM, de Lange MMA, Wielders CCH, Rietveld A, et al
    Incidence and severity of SARS-CoV-2 infection in former Q fever patients as compared to the Dutch population, 2020-2021.
    Epidemiol Infect. 2022;150:e116.
    PubMed         Abstract available
    
    
32. RAY I, Hasan MM, Shah PA, Sahito AM, et al
    HIV epidemic amidst COVID-19 pandemic in India: a conundrum for the country's healthcare system.
    Epidemiol Infect. 2022;150:e112.
    PubMed         Abstract available
    
    
33. XU X, Zhang K, Ma H, Shen X, et al
    Differences in service and antibiotics use following symptomatic respiratory tract infections between 2016 and 2021 in rural Anhui, China.
    Epidemiol Infect. 2022;150:e117.
    PubMed         Abstract available
    
    
34. THOMAS DR, Fina LH, Adamson JP, Sawyer C, et al
    Social, demographic and behavioural determinants of SARS-CoV-2 infection: a case-control study carried out during mass community testing of asymptomatic individuals in South Wales, December 2020.
    Epidemiol Infect. 2022;150:e115.
    PubMed         Abstract available
    
    

    
    Eur J Epidemiol

35. VERBERK JDM, de Hoog MLA, Westerhof I, van Goethem S, et al
    Transmission of SARS-CoV-2 within households: a remote prospective cohort study in European countries.
    Eur J Epidemiol. 2022;37:549-561.
    PubMed         Abstract available
    
    
36. CASPERSEN IH, Magnus P, Trogstad L
    Excess risk and clusters of symptoms after COVID-19 in a large Norwegian cohort.
    Eur J Epidemiol. 2022;37:539-548.
    PubMed         Abstract available
    
    

    
    J Clin Microbiol

37. RODINO KG, Peaper DR, Kelly BJ, Bushman F, et al
    Partial ORF1ab Gene Target Failure with Omicron BA.2.12.1.
    J Clin Microbiol. 2022;60:e0060022.
    PubMed         Abstract available
    
    
38. DESCHERMEIER C, Ehmen C, von Possel R, Murawski C, et al
    Fcgamma-Receptor-Based Enzyme-Linked Immunosorbent Assays for Sensitive, Specific, and Persistent Detection of Anti-SARS-CoV-2 Nucleocapsid Protein IgG Antibodies in Human Sera.
    J Clin Microbiol. 2022;60:e0007522.
    PubMed         Abstract available
    
    
39. MISRA A, Theel ES
    Immunity to SARS-CoV-2: What Do We Know and Should We Be Testing for It?
    J Clin Microbiol. 2022;60:e0048221.
    PubMed         Abstract available
    
    

    
    J Exp Med

40. ZHANG Q, Matuozzo D, Le Pen J, Lee D, et al
    Recessive inborn errors of type I IFN immunity in children with COVID-19 pneumonia.
    J Exp Med. 2022;219.
    PubMed         Abstract available
    
    
41. PLANCHAIS C, Fernandez I, Bruel T, de Melo GD, et al
    Potent human broadly SARS-CoV-2-neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2.
    J Exp Med. 2022;219.
    PubMed         Abstract available
    
    

    
    J Infect Dis

42. ACOSTA-AMPUDIA Y, Monsalve DM, Rojas M, Rodriguez Y, et al
    Persistent Autoimmune Activation and Proinflammatory State in Post-Coronavirus Disease 2019 Syndrome.
    J Infect Dis. 2022;225:2155-2162.
    PubMed         Abstract available
    
    
43. VEDHARA K, Ayling K, Jia R, Fairclough L, et al
    Relationship Between Anxiety, Depression, and Susceptibility to Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Proof of Concept.
    J Infect Dis. 2022;225:2137-2141.
    PubMed         Abstract available
    
    
44. TURNBULL J, Jha RR, Ortori CA, Lunt E, et al
    Serum Levels of Proinflammatory Lipid Mediators and Specialized Proresolving Molecules Are Increased in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 and Correlate With Markers of the Adaptive Immune Response.
    J Infect Dis. 2022;225:2142-2154.
    PubMed         Abstract available
    
    
45. CHANG YH, Kao CC, Fang JJ, Lee YH, et al
    Correspondence to Morbidity and Mortality Among Adults Experiencing Homelessness Hospitalized With Coronavirus Disease 2019.
    J Infect Dis. 2022;225:2235.
    PubMed        
    
    
46. PHIJFFER EWEM, Bont LJ
    Are we ready for maternal RSV vaccination?
    J Infect Dis. 2021 Dec 21. pii: 6472740. doi: 10.1093.
    PubMed        
    
    
47. PETERSON JT, Zareba AM, Fitz-Patrick D, Essink BJ, et al
    Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F Vaccine When Co-Administered With a Tetanus, Diphtheria, and Acellular Pertussis Vaccine.
    J Infect Dis. 2021 Oct 12. pii: 6391485. doi: 10.1093.
    PubMed         Abstract available
    
    
48. SCHWARZ TF, Johnson C, Grigat C, Apter D, et al
    Three dose levels of a maternal respiratory syncytial virus vaccine candidate are well tolerated and immunogenic in a randomized trial in non-pregnant women.
    J Infect Dis. 2021 Jun 19. pii: 6306104. doi: 10.1093.
    PubMed         Abstract available
    
    
49. DEVINCENZO J, Cass L, Murray A, Woodward K, et al
    Safety and Antiviral Effects of Nebulized PC786 in a Respiratory Syncytial Virus Challenge Study.
    J Infect Dis. 2022;225:2087-2096.
    PubMed         Abstract available
    
    
50. NYAWANDA BO, Otieno NA, Otieno MO, Emukule GO, et al
    The Impact of Maternal Human Immunodeficiency Virus Infection on the Burden of Respiratory Syncytial Virus Among Pregnant Women and Their Infants, Western Kenya.
    J Infect Dis. 2022;225:2097-2105.
    PubMed         Abstract available
    
    

    
    J Virol

51. LIU H, Bai Y, Zhang X, Gao T, et al
    SARS-CoV-2 N Protein Antagonizes Stress Granule Assembly and IFN Production by Interacting with G3BPs to Facilitate Viral Replication.
    J Virol. 2022 Jun 2:e0041222. doi: 10.1128/jvi.00412.
    PubMed         Abstract available
    
    

    
    JAMA

52. RUBIN R
    Baricitinib Is First Approved COVID-19 Immunomodulatory Treatment.
    JAMA. 2022;327:2281.
    PubMed        
    
    
53. LARKIN HD
    mRNA COVID-19 Vaccine Booster After Inactivated Vaccine Primary Series.
    JAMA. 2022;327:2280.
    PubMed        
    
    
54. LARKIN HD
    Maternal RSV Vaccine Could Protect Infants, Interim Analysis Suggests.
    JAMA. 2022;327:2182.
    PubMed        
    
    
55. LARKIN HD
    Urine Test Detects SARS-CoV-2 Antibodies.
    JAMA. 2022;327:2182.
    PubMed        
    
    
56. FARMAKIOTIS D
    COVID-19 Treatments for Nonhospitalized Patients.
    JAMA. 2022;327:2247.
    PubMed        
    
    
57. CAYLEY WE JR
    COVID-19 Treatments for Nonhospitalized Patients.
    JAMA. 2022;327:2248.
    PubMed        
    
    
58. GANDHI RT, Malani PN, Del Rio C
    COVID-19 Treatments for Nonhospitalized Patients-Reply.
    JAMA. 2022;327:2248.
    PubMed        
    
    
59. RUBIN R
    Challenges of Deciding Whether and How to Update COVID-19 Vaccines to Protect Against Variants.
    JAMA. 2022 Jun 1. pii: 2793149. doi: 10.1001/jama.2022.9367.
    PubMed        
    
    
60. RUBIN R
    SARS-CoV-2 RNA Can Persist in Stool Months After Respiratory Tract Clears Virus.
    JAMA. 2022 May 18. pii: 2792688. doi: 10.1001/jama.2022.7892.
    PubMed        
    
    
61. BELLANDI D, Voelker R
    New White House COVID-19 Leader on What's Next.
    JAMA. 2022 May 18. pii: 2792686. doi: 10.1001/jama.2022.8541.
    PubMed        
    
    
62. FLEMING-DUTRA KE, Britton A, Shang N, Derado G, et al
    Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance.
    JAMA. 2022 May 13. pii: 2792524. doi: 10.1001/jama.2022.7493.
    PubMed         Abstract available
    
    
63. RAZZAGHI H, Meghani M, Crane B, Ellington S, et al
    Receipt of COVID-19 Booster Dose Among Fully Vaccinated Pregnant Individuals Aged 18 to 49 Years by Key Demographics.
    JAMA. 2022 Apr 22. pii: 2791659. doi: 10.1001/jama.2022.6834.
    PubMed        
    
    

    
    Lancet

64. ANTONELLI M, Pujol JC, Spector TD, Ourselin S, et al
    Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2.
    Lancet. 2022;399:2263-2264.
    PubMed        
    
    
65. OFRI D
    Memorialising COVID-19.
    Lancet. 2022;399:2260-2261.
    PubMed        
    
    

    
    MMWR Morb Mortal Wkly Rep

66. KAMBHAMPATI AK, Burke RM, Dietz S, Sheppard M, et al
    Trends in Acute Hepatitis of Unspecified Etiology and Adenovirus Stool Testing Results in Children - United States, 2017-2022.
    MMWR Morb Mortal Wkly Rep. 2022;71:797-802.
    PubMed         Abstract available
    
    
67. LEE D, Counard C, Tang A, Brister S, et al
    Notes from the Field: COVID-19-Associated Mortality Risk Among Long-Term Care Facility Residents and Community-Dwelling Adults Aged >/=65 Years - Illinois, December 2020 and January 2022.
    MMWR Morb Mortal Wkly Rep. 2022;71:803-805.
    PubMed        
    
    
68. YUAN Y, Thierry JM, Bull-Otterson L, Yeargin-Allsopp M, et al
    COVID-19 Cases and Hospitalizations Among Medicare Beneficiaries With and Without Disabilities - United States, January 1, 2020-November 20, 2021.
    MMWR Morb Mortal Wkly Rep. 2022;71:791-796.
    PubMed         Abstract available
    
    

    
    N Engl J Med

69. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Vaccinating Young Children against Covid-19.
    N Engl J Med. 2022;386:e77.
    PubMed        
    
    
70. GRIFFIN MR
    A Challenge to Respiratory Syncytial Virus Illness in Adults.
    N Engl J Med. 2022;386:2427-2428.
    PubMed        
    
    
71. SCHMOELE-THOMA B, Zareba AM, Jiang Q, Maddur MS, et al
    Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study.
    N Engl J Med. 2022;386:2377-2386.
    PubMed         Abstract available
    
    
72. RUBIN EJ, Baden LR, Abraham J, Morrissey S, et al
    Audio Interview: Viral Evolution and the Future of Monoclonal Antibodies.
    N Engl J Med. 2022;386:e75.
    PubMed        
    
    
73. JOLOBE OMP
    Protection Due to Previous SARS-CoV-2 Infection.
    N Engl J Med. 2022;386.
    PubMed        
    
    
74. SCHERER EM, Babiker A, Adelman MW, Allman B, et al
    SARS-CoV-2 Evolution and Immune Escape in Immunocompromised Patients.
    N Engl J Med. 2022 Jun 8. doi: 10.1056/NEJMc2202861.
    PubMed        
    
    
75. ACCORSI EK, Britton A, Shang N, Fleming-Dutra KE, et al
    Effectiveness of Homologous and Heterologous Covid-19 Boosters against Omicron.
    N Engl J Med. 2022 May 25. doi: 10.1056/NEJMc2203165.
    PubMed        
    
    
76. BROWN PE, Fu SH, Bansal A, Newcombe L, et al
    Omicron BA.1/1.1 SARS-CoV-2 Infection among Vaccinated Canadian Adults.
    N Engl J Med. 2022 May 18. doi: 10.1056/NEJMc2202879.
    PubMed        
    
    
77. EVANS JP, Qu P, Zeng C, Zheng YM, et al
    Neutralization of the SARS-CoV-2 Deltacron and BA.3 Variants.
    N Engl J Med. 2022 May 18. doi: 10.1056/NEJMc2205019.
    PubMed        
    
    

    
    PLoS Comput Biol

78. WATERLOW NR, Toizumi M, van Leeuwen E, Thi Nguyen HA, et al
    Evidence for influenza and RSV interaction from 10 years of enhanced surveillance in Nha Trang, Vietnam, a modelling study.
    PLoS Comput Biol. 2022;18:e1010234.
    PubMed         Abstract available
    
    
79. BEESLEY LJ, Osthus D, Del Valle SY
    Addressing delayed case reporting in infectious disease forecast modeling.
    PLoS Comput Biol. 2022;18:e1010115.
    PubMed         Abstract available
    
    

    
    PLoS Med

80. TAKUVA S, Takalani A, Seocharan I, Yende-Zuma N, et al
    Safety evaluation of the single-dose Ad26.COV2.S vaccine among healthcare workers in the Sisonke study in South Africa: A phase 3b implementation trial.
    PLoS Med. 2022;19:e1004024.
    PubMed         Abstract available
    
    
81. WONG CKH, Lau KTK, Xiong X, Au ICH, et al
    Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.
    PLoS Med. 2022;19:e1004018.
    PubMed         Abstract available
    
    

    
    PLoS One

82. BUTT S, Mahmood A, Saleem S
    The role of institutional factors and cognitive absorption on students' satisfaction and performance in online learning during COVID 19.
    PLoS One. 2022;17:e0269609.
    PubMed         Abstract available
    
    
83. LANIER HD, Diaz MI, Saleh SN, Lehmann CU, et al
    Analyzing COVID-19 disinformation on Twitter using the hashtags #scamdemic and #plandemic: Retrospective study.
    PLoS One. 2022;17:e0268409.
    PubMed         Abstract available
    
    
84. KONUKMAN F, Filiz B, Unlu H
    Teachers' perceptions of teaching physical education using online learning during the COVID-19: A quantitative study in Turkey.
    PLoS One. 2022;17:e0269377.
    PubMed         Abstract available
    
    
85. SUART C, Neuman K, Truant R
    The impact of the COVID-19 pandemic on perceived publication pressure among academic researchers in Canada.
    PLoS One. 2022;17:e0269743.
    PubMed         Abstract available
    
    
86. CAO L, Ren J
    Machine learning shows that the Covid-19 pandemic is impacting U.S. public companies unequally by changing risk structures.
    PLoS One. 2022;17:e0269582.
    PubMed         Abstract available
    
    
87. SATO A, Ludwig J, Howell T
    A retrospective cohort study on COVID-19 at 2 Los Angeles hospitals: Older age, low triage oxygenation, and chronic kidney disease among the top risk factors associated with in-hospital mortality.
    PLoS One. 2022;17:e0268688.
    PubMed         Abstract available
    
    
88. BACURAU AGM, Sato APS, Francisco PMSB
    Correction: Reasons for nonadherence to vaccination for influenza among older people in Brazil.
    PLoS One. 2022;17:e0270443.
    PubMed         Abstract available
    
    
89. COHEN-AHARONOV LA, Rebibo-Sabbah A, Yaacov A, Granit RZ, et al
    High throughput SARS-CoV-2 variant analysis using molecular barcodes coupled with next generation sequencing.
    PLoS One. 2022;17:e0253404.
    PubMed         Abstract available
    
    
90. AKILIMALI PZ, Mashinda DK, Lulebo AM, Mafuta EM, et al
    The emergence of COVID-19 in the Democratic Republic of Congo: Community knowledge, attitudes, and practices in Kinshasa.
    PLoS One. 2022;17:e0265538.
    PubMed         Abstract available
    
    
91. SILVEIRA F, da Matta Machado Fernandes L, Paes-Sousa R
    The sustainable health Agenda in the Americas: Pre-pandemic gaps and 2030 estimates of the SDGs indicators.
    PLoS One. 2022;17:e0270301.
    PubMed         Abstract available
    
    
92. CHEN X, Gao H, Shu B, Zou Y, et al
    Effects of changes in physical and sedentary behaviors on mental health and life satisfaction during the COVID-19 pandemic: Evidence from China.
    PLoS One. 2022;17:e0269237.
    PubMed         Abstract available
    
    
93. TAKEUCHI M, Esaki A, Higa Y, Nakazono A, et al
    Temporal changes in spike IgG levels after two doses of BNT162b2 vaccine in Japanese healthcare workers: Do spike IgG levels at 3 months predict levels 6 or 8 months after vaccination?
    PLoS One. 2022;17:e0263486.
    PubMed         Abstract available
    
    
94. CASTILLO-RODRIGUEZ L, Malo-Sanchez D, Diaz-Jimenez D, Garcia-Velasquez I, et al
    Economic costs of severe seasonal influenza in Colombia, 2017-2019: A multi-center analysis.
    PLoS One. 2022;17:e0270086.
    PubMed         Abstract available
    
    
95. PORTA L, Huang SS, Wei C, Su CH, et al
    Effect of methylprednisolone treatment on COVID-19: An inverse probability of treatment weighting analysis.
    PLoS One. 2022;17:e0266901.
    PubMed         Abstract available
    
    
96. JIANG Y, Mosquera L, Jiang B, Kong L, et al
    Measuring re-identification risk using a synthetic estimator to enable data sharing.
    PLoS One. 2022;17:e0269097.
    PubMed         Abstract available
    
    
97. CASTRO-GUTIERREZ V, Hassard F, Vu M, Leitao R, et al
    Monitoring occurrence of SARS-CoV-2 in school populations: A wastewater-based approach.
    PLoS One. 2022;17:e0270168.
    PubMed         Abstract available
    
    
98. SAHA S
    Death and invasive mechanical ventilation risk in hospitalized COVID-19 patients treated with anti-SARS-CoV-2 monoclonal antibodies and/or antiviral agents: A systematic review and network meta-analysis protocol.
    PLoS One. 2022;17:e0270196.
    PubMed         Abstract available
    
    
99. SMYTH B
    The fading impact of lockdowns: A data analysis of the effectiveness of Covid-19 travel restrictions during different pandemic phases.
    PLoS One. 2022;17:e0269774.
    PubMed         Abstract available
    
    
100. BOONPATCHARANON S, Heffernan JM, Jankowski H
     Estimating the basic reproduction number at the beginning of an outbreak.
     PLoS One. 2022;17:e0269306.
     PubMed         Abstract available
     
     
101. KLUWE-SCHIAVON B, De Zorzi L, Meireles J, Leite J, et al
     The psychological impact of the COVID-19 pandemic in Portugal: The role of personality traits and emotion regulation strategies.
     PLoS One. 2022;17:e0269496.
     PubMed         Abstract available
     
     
102. WILSON KS, Ntlebi V, Made F, Sanabria N, et al
     COVID-19 cases among medical laboratory services staff in South Africa, 2020-2021: A cohort study.
     PLoS One. 2022;17:e0268998.
     PubMed         Abstract available
     
     
103. ETAJURI EA, Mohd NR, Naimie Z, Ahmad NA, et al
     Undergraduate dental students' perspective of online learning and their physical and mental health during COVID-19 pandemic.
     PLoS One. 2022;17:e0270091.
     PubMed         Abstract available
     
     
104. WU Y, Zhang T, Ye Z, Chen K, et al
     Public anxiety through various stages of COVID-19 coping: Evidence from China.
     PLoS One. 2022;17:e0270229.
     PubMed         Abstract available
     
     
105. BLESZYNSKI J, Ruminska A, Hamerlinska A, Stefanska-Klar R, et al
     The experience of the COVID-19 pandemic by persons with ASD: Social aspects.
     PLoS One. 2022;17:e0267123.
     PubMed         Abstract available
     
     
106. CORDOVA-LEPE F, Vogt-Geisse K
     Adding a reaction-restoration type transmission rate dynamic-law to the basic SEIR COVID-19 model.
     PLoS One. 2022;17:e0269843.
     PubMed         Abstract available
     
     
107. SMITH ER, Oakley E, He S, Zavala R, et al
     Protocol for a sequential, prospective meta-analysis to describe coronavirus disease 2019 (COVID-19) in the pregnancy and postpartum periods.
     PLoS One. 2022;17:e0270150.
     PubMed         Abstract available
     
     
108. SASSI FC, Ritto AP, de Lima MS, Valente Junior CN, et al
     Characteristics of postintubation dysphagia in ICU patients in the context of the COVID-19 outbreak: A report of 920 cases from a Brazilian reference center.
     PLoS One. 2022;17:e0270107.
     PubMed         Abstract available
     
     
109. BESUTTI G, Djuric O, Ottone M, Monelli F, et al
     Imaging-based indices combining disease severity and time from disease onset to predict COVID-19 mortality: A cohort study.
     PLoS One. 2022;17:e0270111.
     PubMed         Abstract available
     
     
110. ACHENBACH CJ, Caputo M, Hawkins C, Balmert LC, et al
     Clinical evaluation of the Diagnostic Analyzer for Selective Hybridization (DASH): A point-of-care PCR test for rapid detection of SARS-CoV-2 infection.
     PLoS One. 2022;17:e0270060.
     PubMed         Abstract available
     
     
111. HERTLING S, Hertling D, Matziolis G, Schleussner E, et al
     Digital teaching tools in sports medicine: A randomized control trial comparing the effectiveness of virtual seminar and virtual fishbowl teaching method in medical students.
     PLoS One. 2022;17:e0267144.
     PubMed         Abstract available
     
     
112. MEISTER T, Pisarev H, Kolde R, Kalda R, et al
     Clinical characteristics and risk factors for COVID-19 infection and disease severity: A nationwide observational study in Estonia.
     PLoS One. 2022;17:e0270192.
     PubMed         Abstract available
     
     
113. TAYLOR JD, McCann MH, Richter SJ, Matson D, et al
     Impact of local mask mandates upon COVID-19 case rates in Oklahoma.
     PLoS One. 2022;17:e0269339.
     PubMed         Abstract available
     
     
114. BARROS-AREAL AF, Albuquerque CP, Silva NM, Pinho RDNL, et al
     Impact of COVID-19 on the mental health of public university hospital workers in Brazil: A cohort-based analysis of 32,691 workers.
     PLoS One. 2022;17:e0269318.
     PubMed         Abstract available
     
     
115. KIM KS, Kim JH, Roh JH, Kim D, et al
     Ability and accuracy of the smartphone-based O`VIEW-M(R) sperm test: Useful tool in the era of Covid-19.
     PLoS One. 2022;17:e0269894.
     PubMed         Abstract available
     
     
116. TOLOSSA T, Merdassa Atomssa E, Fetensa G, Bayisa L, et al
     Acute respiratory distress syndrome among patients with severe COVID-19 admitted to treatment center of Wollega University Referral Hospital, Western Ethiopia.
     PLoS One. 2022;17:e0267835.
     PubMed         Abstract available
     
     
117. KONLAN KD, Asampong E, Dako-Gyeke P, Glozah FN, et al
     Burnout syndrome among healthcare workers during COVID-19 Pandemic in Accra, Ghana.
     PLoS One. 2022;17:e0268404.
     PubMed         Abstract available
     
     
118. SCHOSSER J
     Fairness in the use of limited resources during a pandemic.
     PLoS One. 2022;17:e0270022.
     PubMed         Abstract available
     
     
119. LIANG AL, Turner LC, Voegtline KM, Olson SB, et al
     Impact of COVID-19 on gynecologic and obstetrical services at two large health systems.
     PLoS One. 2022;17:e0269852.
     PubMed         Abstract available
     
     
120. ABAY ES, Belew MD, Ketsela BS, Mengistu EE, et al
     Assessment of attitude towards COVID-19 vaccine and associated factors among clinical practitioners in Ethiopia: A cross-sectional study.
     PLoS One. 2022;17:e0269923.
     PubMed         Abstract available
     
     
121. FREIRE ML, Alves LL, de Souza CS, Saliba JW, et al
     Performance differences among commercially available antigen rapid tests for COVID-19 in Brazil.
     PLoS One. 2022;17:e0269997.
     PubMed         Abstract available
     
     
122. LI L, Wang F, Shui X, Liang Q, et al
     Knowledge, attitudes, and practices towards COVID-19 among college students in China: A systematic review and meta-analysis.
     PLoS One. 2022;17:e0270038.
     PubMed         Abstract available
     
     
123. BARCHUK A, Skougarevskiy D, Kouprianov A, Shirokov D, et al
     COVID-19 pandemic in Saint Petersburg, Russia: Combining population-based serological study and surveillance data.
     PLoS One. 2022;17:e0266945.
     PubMed         Abstract available
     
     
124. SCHAFFER AL, Henry D, Zoega H, Elliott JH, et al
     Changes in dispensing of medicines proposed for re-purposing in the first year of the COVID-19 pandemic in Australia.
     PLoS One. 2022;17:e0269482.
     PubMed         Abstract available
     
     
125. BOGUSZEWSKI R, Makowska M, Podkowinska M
     Changes in intensification of religious involvement during the COVID-19 pandemic in Poland.
     PLoS One. 2022;17:e0269015.
     PubMed         Abstract available
     
     
126. DE ANDRADE PEREIRA SILVA M, Ribeiro HF, Oliveira RR, Pelloso FC, et al
     Factors associated with vaccination against Covid-19 in pregnant and hospitalized postpartum women: A retrospective cohort study.
     PLoS One. 2022;17:e0269091.
     PubMed         Abstract available
     
     
127. KLEINMAN D, Morgan AM, Ostrand R, Wittenberg E, et al
     Lasting effects of the COVID-19 pandemic on language processing.
     PLoS One. 2022;17:e0269242.
     PubMed         Abstract available
     
     
128. ALENQUER M, Milheiro Silva T, Akpogheneta O, Ferreira F, et al
     Saliva molecular testing bypassing RNA extraction is suitable for monitoring and diagnosing SARS-CoV-2 infection in children.
     PLoS One. 2022;17:e0268388.
     PubMed         Abstract available
     
     
129. GU M, Taylor B, Pollack HA, Schneider JA, et al
     A pilot study on COVID-19 vaccine hesitancy among healthcare workers in the US.
     PLoS One. 2022;17:e0269320.
     PubMed         Abstract available
     
     
130. ZAMAN N, Parvaiz N, Farid R, Navid A, et al
     Senna makki and other active phytochemicals: Myths and realities behind covid19 therapeutic interventions.
     PLoS One. 2022;17:e0268454.
     PubMed         Abstract available
     
     
131. RANI MDM, Mohamed NA, Solehan HM, Ithnin M, et al
     Assessment of acceptability of the COVID-19 vaccine based on the health belief model among Malaysians-A qualitative approach.
     PLoS One. 2022;17:e0269059.
     PubMed         Abstract available
     
     
132. KHAMI MR, Gholamhossein Zadeh A, Rahi D
     A cross-sectional study on COVID-19-related changes in self-medication with antibiotics.
     PLoS One. 2022;17:e0269782.
     PubMed         Abstract available
     
     
133. HARKE NN, Wagner C, Hermann RM, Hadaschik BA, et al
     Lessons learned after one year of COVID-19 from a urologist and radiotherapist view: A German survey on prostate cancer diagnosis and treatment.
     PLoS One. 2022;17:e0269827.
     PubMed         Abstract available
     
     
134. CHEN Y, Zhou X, Liu J, Li R, et al
     Effect of internet-delivered cognitive behavioral therapy on insomnia in convalescent patients with COVID-19: Protocol for a systematic review and meta-analysis.
     PLoS One. 2022;17:e0269882.
     PubMed         Abstract available
     
     
135. OLIVA G, Schlueter M, Munetomo M, Scala A, et al
     Dynamical intervention planning against COVID-19-like epidemics.
     PLoS One. 2022;17:e0269830.
     PubMed         Abstract available
     
     

     
     Proc Natl Acad Sci U S A

136. DIEDERICHS M, van Ewijk R, Isphording IE, Pestel N, et al
     Schools under mandatory testing can mitigate the spread of SARS-CoV-2.
     Proc Natl Acad Sci U S A. 2022;119:e2201724119.
     PubMed         Abstract available
     
     
137. HU M, Qiu Z, Bi Z, Tian T, et al
     Photocontrolled crRNA activation enables robust CRISPR-Cas12a diagnostics.
     Proc Natl Acad Sci U S A. 2022;119:e2202034119.
     PubMed         Abstract available
     
     
138. SHEN Y, Courtney JM, Anfinrud P, Bax A, et al
     Hybrid measurement of respiratory aerosol reveals a dominant coarse fraction resulting from speech that remains airborne for minutes.
     Proc Natl Acad Sci U S A. 2022;119:e2203086119.
     PubMed         Abstract available
     
     
139. LIMA DE MIRANDA K, Snower DJ
     The societal responses to COVID-19: Evidence from the G7 countries.
     Proc Natl Acad Sci U S A. 2022;119:e2117155119.
     PubMed         Abstract available
     
     
140. QIN C, Rao Y, Yuan H, Wang TY, et al
     SARS-CoV-2 couples evasion of inflammatory response to activated nucleotide synthesis.
     Proc Natl Acad Sci U S A. 2022;119:e2122897119.
     PubMed         Abstract available
     
     

     
     Vaccine

141. CANADAY LM, Resnick JD, Liu H, Powell H, et al
     HA and M2 sequences alter the replication of 2013-16 H1 live attenuated influenza vaccine infection in human nasal epithelial cell cultures.
     Vaccine. 2022 Jun 16. pii: S0264-410X(22)00733.
     PubMed         Abstract available
     
     
142. BRAUNFELD JB, Carson HN, Williams SR, Schwartz LM, et al
     Clinical endpoints to inform vaccine policy: A systematic review of outcome measures from pediatric influenza vaccine efficacy trials.
     Vaccine. 2022 Jun 15. pii: S0264-410X(22)00778.
     PubMed         Abstract available
     
     
143. MOGHNIEH R, Abdallah D, Sayegh MH, Rahman Bizri A, et al
     Response to letter to the editor: Immunophenotyping of SARS-CoV-2 and vaccine design.
     Vaccine. 2022;40:3987-3988.
     PubMed        
     
     
144. CIMOLAI N
     Immunophenotyping of SARS-CoV-2 and vaccine design.
     Vaccine. 2022;40:3985-3986.
     PubMed        
     
     
145. CHUNG JR, Kim SS, Flannery B, Smith ME, et al
     Vaccine-associated attenuation of subjective severity among outpatients with influenza.
     Vaccine. 2022 Jun 14. pii: S0264-410X(22)00767.
     PubMed         Abstract available
     
     
146. ZHAO FJ, Liu LT, Wang Z, Wang NX, et al
     Development and immunogenicity evaluation of porcine deltacoronavirus inactivated vaccine with different adjuvants in mice.
     Vaccine. 2022 Jun 9. pii: S0264-410X(22)00721.
     PubMed         Abstract available
     
     
147. HASHIMOTO M, Nagata N, Homma T, Maeda H, et al
     Immunogenicity and protective efficacy of SARS-CoV-2 recombinant S-protein vaccine S-268019-b in cynomolgus monkeys.
     Vaccine. 2022 Jun 6. pii: S0264-410X(22)00718.
     PubMed         Abstract available
     
     
148. EUGENIA-TOLEDO-ROMANI M, Verdecia-Sanchez L, Rodriguez-Gonzalez M, Rodriguez-Noda L, et al
     Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials.
     Vaccine. 2022 Jun 6. pii: S0264-410X(22)00717.
     PubMed         Abstract available
     
     
149. TOOR J, Li X, Jit M, Trotter CL, et al
     COVID-19 impact on routine immunisations for vaccine-preventable diseases: Projecting the effect of different routes to recovery.
     Vaccine. 2022 May 30. pii: S0264-410X(22)00698.
     PubMed         Abstract available
     
     
150. WOO EJ, Dimova RB
     Thrombocytopenia after Ad.26.COV2.S COVID-19 vaccine: Reports to the vaccine adverse event reporting system.
     Vaccine. 2022 May 30. pii: S0264-410X(22)00704.
     PubMed         Abstract available
     
     
151. NOWALK MP, D'Agostino H, Dauer K, Stiegler M, et al
     Estimating the burden of adult hospitalized RSV infection including special populations.
     Vaccine. 2022;40:4121-4127.
     PubMed         Abstract available
     
     
152. PATEL KM, Shafiq M, Malik AA, Cobanoglu A, et al
     Relationship between the use of nonpharmaceutical interventions and COVID-19 vaccination among U.S. child care providers: A prospective cohort study.
     Vaccine. 2022 May 27. pii: S0264-410X(22)00680.
     PubMed         Abstract available
     
     
153. WILSON B, Mukundan Geetha K
     Nanomedicine to deliver biological macromolecules for treating COVID-19.
     Vaccine. 2022;40:3931-3941.
     PubMed         Abstract available
     
     
154. MERRICK E, Weissman JP, Patel SJ
     Utilizing Google trends to monitor coronavirus vaccine interest and hesitancies.
     Vaccine. 2022 May 30. pii: S0264-410X(22)00699.
     PubMed         Abstract available
     
     
155. SOEGIARTO G, Wulandari L, Purnomosari D, Dhia Fahmita K, et al
     Hypertension is associated with antibody response and breakthrough infection in health care workers following vaccination with inactivated SARS-CoV-2.
     Vaccine. 2022 May 27. pii: S0264-410X(22)00676.
     PubMed         Abstract available
     
     
156. SALMANTON-GARCIA J, Stewart FA, Heringer S, Koniordou M, et al
     VACCELERATE Volunteer Registry: A European study participant database to facilitate clinical trial enrolment.
     Vaccine. 2022;40:4090-4097.
     PubMed         Abstract available
     
     
157. DUBE C, Paris-Robidas S, Andreani G, Gutzeit C, et al
     Broad neutralization against SARS-CoV-2 variants induced by ancestral and B.1.351 AS03-Adjuvanted recombinant Plant-Derived Virus-Like particle vaccines.
     Vaccine. 2022 May 27. pii: S0264-410X(22)00641.
     PubMed         Abstract available
     
     
158. LEIGH JP, Moss SJ, White TM, Picchio CA, et al
     Factors affecting COVID-19 vaccine hesitancy among healthcare providers in 23 countries.
     Vaccine. 2022 May 5. pii: S0264-410X(22)00545.
     PubMed         Abstract available
     
     
159. SHAPIRO BEN DAVID S, Mizrahi B, Rahamim-Cohen D, Supino-Rosin L, et al
     Robust antibody response after a third BNT162b2 vaccine compared to the second among immunocompromised and healthy individuals, a prospective longitudinal cohort study.
     Vaccine. 2022 May 28. pii: S0264-410X(22)00668.
     PubMed         Abstract available
     
     
160. DUBE E, Gagnon D, MacDonald N
     Between persuasion and compulsion: The case of COVID-19 vaccination in Canada.
     Vaccine. 2022 May 25. pii: S0264-410X(22)00670.
     PubMed        
     
     
161. BECK E, Biundo E, Devlin N, Doherty TM, et al
     Capturing the value of vaccination within health technology assessment and health economics: Literature review and novel conceptual framework.
     Vaccine. 2022 May 23. pii: S0264-410X(22)00490.
     PubMed         Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Influenza is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: